AI-Powered Heart Scanning Breakthrough Secures $6M to Battle Leading Killer
DESKi Secures $6 Million Seed Funding
DESKi, a leading healthtech company, has successfully raised $6 million in a seed funding round. This investment will help DESKi launch its FDA-approved cardiac imaging software, HeartFocus, in the U.S. and other global markets. The achievement marks a significant milestone in DESKi's mission to enhance heart disease diagnostics using advanced technology.
Support from Prominent European Investors
The seed round was led by Racine², an impact-focused fund managed by Serena and Makesense. Other notable participants include BNP Paribas Développement, Épopée Gestion, Good Only Ventures, Better Angle, and NACO. These investors are aligned with DESKi’s vision to make early, AI-enabled cardiac care accessible worldwide, bringing not only capital but also valuable expertise to the company.
HeartFocus: A Game-Changer in Cardiac Imaging
HeartFocus recently received FDA clearance, ensuring its reliability and safety. The software features a Predetermined Change Control Plan (PCCP), which allows for easy updates and expansions in the future. Clinical studies have demonstrated that even first-time users, guided by HeartFocus AI, can capture high-quality heart scans, making advanced cardiac imaging more accessible.
Vision for Early Heart Disease Detection
Dr. Bertrand Moal, CEO and co-founder of DESKi, emphasizes the goal of making early heart disease detection available at any point of care. The funding will enable DESKi to continue improving HeartFocus and expanding its reach. By empowering more healthcare providers with essential diagnostic tools, DESKi aims to save lives through timely heart disease diagnosis.
Bridging the Gap in Cardiac Care
Heart disease is the leading cause of death globally, yet access to echocardiography is limited due to a shortage of trained specialists. HeartFocus addresses this issue by providing real-time AI guidance, allowing any healthcare professional to perform cardiac ultrasounds with just a few hours of training. This innovation ensures that early diagnosis is possible in primary care, rural clinics, and other resource-limited settings.
Investors' Confidence in DESKi
Léa Zaslavsky from Racine² highlights DESKi’s commitment to solving urgent healthcare challenges. Sophie Pierrin Lepinard from BNPParibas Développement believes HeartFocus can transform cardiovascular disease management with faster and broader access. Camille Le Roux Larsabal of Épopée Gestion and other investors expressed their pride and excitement to support DESKi’s international expansion and real-world impact.
Conclusion
With the successful seed funding round, DESKi is poised to revolutionize cardiac care through its innovative HeartFocus software. The support from leading investors and the FDA approval underscore the potential of HeartFocus to make a significant impact on heart disease detection and management. DESKi continues to drive forward its mission to democratize access to life-saving cardiac diagnostics globally.
Read the full article here:
venturebeat.com